Last $0.20 USD
Change Today 0.00 / 0.00%
Volume 25.0K
TNGN On Other Exchanges
Symbol
Exchange
OTC US
As of 12:22 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

tengion inc (TNGN) Snapshot

Open
$0.19
Previous Close
$0.20
Day High
$0.20
Day Low
$0.19
52 Week High
07/18/13 - $1.39
52 Week Low
04/14/14 - $0.15
Market Cap
3.6M
Average Volume 10 Days
137.5K
EPS TTM
$-8.20
Shares Outstanding
18.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TENGION INC (TNGN)

Related News

No related news articles were found.

tengion inc (TNGN) Related Businessweek News

No Related Businessweek News Found

tengion inc (TNGN) Details

Tengion, Inc. operates as a regenerative medicine company. The company focuses on discovering, developing, manufacturing, and commercializing a range of neo-organs or products composed of living cells with or without synthetic or natural materials that are implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. Its product portfolio includes Neo-Kidney Augment to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease; and Neo-Urinary Conduit, which is in Phase I clinical trial and used to replace the use of bowel tissue in bladder cancer patients requiring a non-continent urinary diversion after bladder removal surgery. The company has a license agreement with Children’s Medical Center Corporation (CMCC) for the license of certain patent rights and intellectual property rights owned or controlled by CMCC related to tissue engineering technology. Tengion, Inc. was founded in 2003 and is headquartered in Winston-Salem, North Carolina.

25 Employees
Last Reported Date: 04/9/14
Founded in 2003

tengion inc (TNGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $462.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $336.6K
Chief Scientific Officer and President of Res...
Total Annual Compensation: $380.8K
Compensation as of Fiscal Year 2013.

tengion inc (TNGN) Key Developments

Tengion, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

Tengion, Inc. announced unaudited earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported loss from operations of $4,472,000 against $3,795,000 for the same period a year ago. Net income was $6,039,000 or $1.06 per share basic and diluted against net loss of $4,089,000 or $1.72 loss per share basic and diluted for the same period a year ago. Adjusted net loss was $6,292,000 or $1.10 loss per share against $5,908,000 or $2.49 for the same period a year ago. The increased adjusted net loss for the 2013 period was primarily due to an increase in research and development expense of $0.5 million related to the Phase 1 clinical trial of the Company's Neo-Kidney Augment initiated in May 2013 at the Karolinska Institute in Stockholm, Sweden. For the full year, the company reported loss from operations of $16,597,000 against $16,220,000 for the same period a year ago. Net loss was $18,927,000 or $4.70 per share basic and diluted against $16,929,000 or $7.13 loss per share basic and diluted for the same period a year ago. Adjusted net loss was $23,617,000 or $5.87 loss per share against $18,985,000 or $8.00 for the same period a year ago. The increased adjusted net loss for the 2013 period was primarily due to increases in interest expense of $4.7 million and in general and administrative expense of $0.8 million, offset in part by a decrease in research and development expense of $0.6 million and depreciation expense of $0.2 million.

Tengion, Inc. Auditor Raises 'Going Concern' Doubt

Tengion, Inc. filed its 10-K on Mar 26, 2014 for the period ending Dec 31, 2013. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Tengion, Inc. Presents at 26th Annual ROTH Conference, Mar-10-2014 12:30 PM

Tengion, Inc. Presents at 26th Annual ROTH Conference, Mar-10-2014 12:30 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: John L. Miclot, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNGN:US $0.20 USD 0.00

TNGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TNGN.
View Industry Companies
 

Industry Analysis

TNGN

Industry Average

Valuation TNGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TENGION INC, please visit www.tengion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.